A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
Drugs used for their effects on the respiratory system.
Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM.
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.

Inhaled NO and almitrine bismesylate in patients with acute respiratory distress syndrome: effect of noradrenalin. (1/32)

The combination of inhaled nitric oxide with almitrine bismesylate has been proposed for the management of acute respiratory distress syndrome in order to divert pulmonary blood flow away from poorly ventilated toward well-ventilated areas. The aims of this prospective and comparative study were to: 1) confirm the beneficial effects on oxygenation of this association; 2) evaluate the haemodynamic effects of this association; and 3) evaluate the influence of noradrenaline (a nonspecific vasoconstrictor) on the modification of gas exchange related to inhaled NO and/or almitrine bismesylate. Forty-one sedated paralysed and ventilated patients were investigated. Haemodynamic and blood gas measurements were performed in a fixed order: baseline; inhalation of NO for 30 min.; intravenous infusion of almitrine bismesylate; and concomitant administration of inhaled NO and almitrine bismesylate. Inhaled NO and almitrine bismesylate increased arterial oxygen tension (Pa,O2)/inspiratory oxygen fraction (FI,O2) (p<0.001). The association of inhaled NO with almitrine bismesylate resulted in a dramatic improvement in Pa,O2/FI,O2 (p<0.0001 versus almitrine bismesylate, p<0.05 versus inhaled NO). In patients receiving noradrenalin (n = 19), almitrine bismesylate had no effect on oxygenation. The present study confirmed that the combination of inhaled NO with almitrine bismesylate improved oxygenation, and demonstrated that almitrine bismesylate has no effect on oxygenation in patients receiving noradrenalin.  (+info)

Effect of inhaled prostacyclin in combination with almitrine on ventilation-perfusion distributions in experimental lung injury. (2/32)

BACKGROUND: Inhaled prostacyclin and intravenous almitrine have both been shown to improve pulmonary gas exchange in acute lung injury (ALI). This study was performed to investigate a possible additive effect of prostacyclin and almitrine on pulmonary ventilation-perfusion (VA/Q) ratio in ALI compared with inhaled prostacyclin or intravenous almitrine alone. METHODS: Experimental ALI was established in 24 pigs by repeated lung lavage. Animals were randomly assigned to receive either 25 ng.kg(-1).min(-1) inhaled prostacyclin alone, 1 microg.kg(-1).min(-1) almitrine alone, 25 ng.kg(-1).min(-1) inhaled prostacyclin in combination with 1 microg.kg(-1).min(-1) almitrine, or no specific treatment (controls) for 30 min. For each intervention, pulmonary gas exchange and hemodynamics were analyzed and VA/Q distributions were calculated using the multiple inert gas elimination technique. The data was analyzed within and between the groups by analysis of variance for repeated measurements, followed by the Student-Newman-Keuls test for multiple comparison when analysis of variance revealed significant differences. RESULTS: All values are expressed as mean +/- SD. In controls, pulmonary gas exchange, hemodynamics, and VA/Q distribution remained unchanged. With prostacyclin alone and almitrine alone, arterial oxygen partial pressure (PaO2) increased, whereas intrapulmonary shunt (QS/QT) decreased (P < 0.05). Combined prostacyclin and almitrine also increased PaO2 and decreased QS/QT (P < 0.05). When compared with either prostacyclin or almitrine alone, the combined application of both drugs revealed no additional effect in gas exchange or VA/Q distribution. CONCLUSIONS: The authors conclude that, in this experimental model of ALI, the combination of 25 ng.kg(-1).min(-1) prostacyclin and 1 microg.kg(-1).min(-1) almitrine does not result in an additive improvement of pulmonary gas exchange or VA/Q distribution when compared with prostacyclin or almitrine alone.  (+info)

Association of oral almitrine and medroxyprogesterone acetate: effect on arterial blood gases in chronic obstructive pulmonary disease. (3/32)

Almitrine (A) and medroxyprogesterone acetate (MA) given separately improve arterial blood gases in some patients with chronic obstructive pulmonary disease (COPD); the aim of this study was to assess the effect of the two drugs given together. Forty-eight patients with irreversible COPD and hypoxaemia were prospectively enrolled into a 14-day run-in period and received single-blind oral treatment with double placebo. Patients whose PaO2 remained stable (less than 10% change; n = 29, 25 males, mean age 65.6 years) were included in a 14-day active treatment period and randomly assigned to three groups. They received double-blind oral treatment with: A (50 mg bid, group A, n = 10); MA (20 mg tid, group MA, n = 9); A (50 mg bid) and MA (20 mg tid, group A+MA, n = 10). Anthropometric and spirometric measurements were similar in the three groups and so were the arterial blood gas values at the beginning and the end of the run-in period. At the end of the active treatment period, blood gas changes (mean+/-SE) were significantly different between groups (P<0.05, Kruskal-Wallis test), with improvement in both hypoxaemia and hypercapnia in group A+MA only: delta PaO2 = 7.4+/-1.9 mmHg, delta PaCO2 = -5.1+/-1.7 m mHg (P<0.05, Wilcoxon test). In short-term treatment, the association of A and MA is more efficient than either drug alone at improving arterial blood gases in COPD patients.  (+info)

Effects of almitrine on diaphragm contractile properties in young and old rats. (4/32)

BACKGROUND: Diaphragm muscle force and fatigue are key factors in the development of respiratory failure. Almitrine is used to improve ventilatory drive and ventilation-perfusion matching in respiratory failure. Recently, it has also been shown to improve diaphragm muscle force and endurance in young rats, but it is not known if this effect persists with ageing. OBJECTIVES: To determine the effects of almitrine on diaphragm contractile properties in young and old rats. METHODS: In young and old rats, isometric contractile properties were measured in strips of isolated diaphragm muscle in physiological saline solution at 30 degrees C with or without almitrine. RESULTS: In young animals, almitrine increased twitch tension, reduced half-relaxation time and increased endurance, but had no effect on tetanic tension, contraction time or tension-frequency relationship. Ageing had no effect on endurance, but did reduce twitch and tetanic tension and contraction and half-relaxation time. Almitrine had no effect on contractile tension and kinetics, tension-frequency relationship or on endurance in the old animals. CONCLUSIONS: Ageing negates the beneficial effects of almitrine on diaphragm muscle force and endurance.  (+info)

An investigation into the mechanism of action of almitrine on isolated rat diaphragm muscle fatigue. (5/32)

BACKGROUND: Previous studies have shown that almitrine bismesylate, a respiratory stimulant which acts on the mitochondrial electron transport chain, enhances recovery of rat diaphragm muscle from fatigue. OBJECTIVES: Our aim is to investigate if the enhanced recovery is due to an anti-oxidant property of almitrine, since the electron transport chain is a major site of intracellular free radical production. METHODS: A low-frequency fatigue protocol was used (30 Hz; 250 ms; delivered once every 2 s for 5 min), and the effects of almitrine before and after fatigue onset were compared to those of the anti-oxidant compound N-acetylcysteine (NAC). RESULTS: Almitrine (6 and 10 microg/ml) given before fatigue gave better recovery rates than postfatigue application. In contrast, NAC (100 microM) application before fatigue onset was not as effective as NAC given immediately after the cessation of the fatigue protocol. However, almitrine (6 microg/ml) completely reversed the reduction in baseline twitch tension brought about by a free-radical-producing mixture of FeCl(3) + ADP (1 mM + 2.5 mM, respectively). CONCLUSION: The results of this study confirm that almitrine enhances recovery from fatigue and, in contrast to NAC prefatigue application, is more effective. Also, almitrine was shown to have an anti-oxidant effect, but it does not act like a typical anti-oxidant.  (+info)

Effect of position, nitric oxide, and almitrine on lung perfusion in a porcine model of acute lung injury. (6/32)

In a porcine model of oleic acid-induced lung injury, the effects of inhaled nitric oxide (iNO) and intravenous almitrine bismesylate (ivALM), which enhances the hypoxic pulmonary vasoconstriction on the distribution of regional pulmonary blood flow (PBF), were assessed. After injection of 0.12 ml/kg oleic acid, 20 anesthetized and mechanically ventilated piglets [weight of 25 +/- 2.6 (SD) kg] were randomly divided into four groups: supine position, prone position, and 10 ppm iNO for 40 min followed by 4 microg x kg(-1) x min(-1) ivALM for 40 min in supine position and in prone position. PBF was measured with positron emission tomography and H(2)15O. The redistribution of PBF was studied on a pixel-by-pixel basis. Positron emission tomography scans were performed before and then 120, 160, and 200 min after injury. With prone position alone, although PBF remained prevalent in the dorsal regions it was significantly redistributed toward the ventral regions (P < 0.001). A ventral redistribution of PBF was also obtained with iNO regardless of the position (P = 0.043). Adjunction of ivALM had no further effect on PBF redistribution. PP and iNO have an additive effect on ventral redistribution of PBF.  (+info)

Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study. (7/32)

BACKGROUND: Advanced chronic obstructive pulmonary disease (COPD) generates high costs, especially when patients require domiciliary long-term oxygen therapy (LTOT). Almitrine bismesylate has been shown to improve gas exchange in the lungs. Our hypothesis was that long-term treatment with almitrine might postpone the prescription of LTOT. OBJECTIVE: To evaluate the effects of almitrine sequential treatment on arterial blood gases in COPD patients with moderate hypoxaemia. METHODS: COPD patients with moderate hypoxaemia [partial oxygen tension in arterialised blood (PaO(2)) between 7.33 and 8.66 kPa (56-65 mm Hg)] were investigated. After a 1-month run-in period, patients were given either almitrine 100 mg per day or placebo for sequential treatment for a total of 12 months. RESULTS: 115 patients in a steady state (57 in the almitrine and 58 in the placebo group) were included. Mean age was 60 years, mean forced expiratory volume in 1 s was 34 +/- 13% of predicted and mean PaO(2) was 8.04 +/- 0.5 kPa (60.5 +/- 3.8 mm Hg). 38 patients were lost to follow-up, 23 in the almitrine and 15 in the placebo group. The majority of drop-outs were due to adverse events (AE; 16 in the almitrine and 9 in the placebo group). Almitrine treatment resulted in PaO(2) improvement of 0.43 +/- 0.88 kPa (3.2 +/- 6.6 mm Hg) (p = 0.003). The treatment effect between almitrine and placebo was 0.45 kPa (3.4 mm Hg) (p = 0.003). In the almitrine group, two distinct subgroups were observed: responders (n = 19) and non-responders (n = 38). Almitrine treatment in responders resulted in a clinically significant improvement in PaO(2) of 1.36 +/- 0.7 kPa (10.2 +/- 5.3 mm Hg) (p < 0.0001) and a reduction of partial carbon dioxide tension in arterialised blood. 31 patients experienced serious AE: 17 in the almitrine and 14 in the placebo group. Five patients died during the study (3 in the almitrine and 2 in the placebo group). Most AE occurring during the study were related to underlying disease. Clinical diagnosis of polyneuropathy resulted in the withdrawal of 5 patients in the almitrine group and 3 patients in the placebo group. Four patients in the almitrine group experienced weight loss. CONCLUSIONS: Almitrine treatment of patients with severe COPD and moderate hypoxaemia resulted in a small but significant improvement in PaO(2) over 12 months. A clinically important improvement in gas exchange was observed in 33% of treated patients. These patients may be candidates for long-term treatment.  (+info)

An analysis of the action of an analogue of almitrine bismesylate in the rat model of hypoxic lung disease. (8/32)

Chronically hypoxic (CH) and normoxic control rats were used to assess the action of S9581, a water-soluble analogue of almitrine bismesylate. S9581 increased ventilation (Ve) by 34% in control and 20% in CH rats. During acute hypoxia Ve was raised and S9581 caused a further increase of 20% in both groups. Low doses of S9581 and almitrine enhanced the hypoxic ventilatory response in CH rats while high doses depressed it in both groups. Effects of S9581 on the pulmonary circulation were assessed in the isolated perfused lung of rats. As with almitrine a complex relationship of dose-dependent vasoconstriction and dilatation was revealed. In low doses, S9581 enhanced the hypoxic pulmonary vasoconstrictor response to 2% O2 whilst this was attenuated by high doses in both control and CH rats. S9581 seemed to act like almitrine bismesylate on both the ventilation (peripheral chemoreceptor) and the pulmonary circulation. For studying almitrine-like activity the water solubility of S9581 provides considerable advantages for the researcher.  (+info)

Almitrine is a medication that was used in the past to treat chronic obstructive pulmonary disease (COPD). It works as a respiratory stimulant, increasing the respiratory drive and improving oxygenation. However, its use has been limited due to its potential cardiovascular side effects, including increased blood pressure and heart rate. Almitrine is no longer approved for use in many countries, including the United States.

Respiratory system agents are substances that affect the respiratory system, which includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs. These agents can be classified into different categories based on their effects:

1. Respiratory Stimulants: Agents that increase respiratory rate or depth by acting on the respiratory center in the brainstem.
2. Respiratory Depressants: Agents that decrease respiratory rate or depth, often as a side effect of their sedative or analgesic effects. Examples include opioids, benzodiazepines, and barbiturates.
3. Bronchodilators: Agents that widen the airways (bronchioles) in the lungs by relaxing the smooth muscle around them. They are used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Examples include albuterol, ipratropium, and theophylline.
4. Anti-inflammatory Agents: Agents that reduce inflammation in the airways, which can help relieve symptoms of asthma, COPD, and other respiratory conditions. Examples include corticosteroids, leukotriene modifiers, and mast cell stabilizers.
5. Antitussives: Agents that suppress coughing, often by numbing the throat or acting on the cough center in the brainstem. Examples include dextromethorphan and codeine.
6. Expectorants: Agents that help thin and loosen mucus in the airways, making it easier to cough up and clear. Examples include guaifenesin and iodinated glycerol.
7. Decongestants: Agents that narrow blood vessels in the nose and throat, which can help relieve nasal congestion and sinus pressure. Examples include pseudoephedrine and phenylephrine.
8. Antimicrobial Agents: Agents that kill or inhibit the growth of microorganisms such as bacteria, viruses, and fungi that can cause respiratory infections. Examples include antibiotics, antiviral drugs, and antifungal agents.

Pulmonary heart disease, also known as cor pulmonale, is a type of heart disease that occurs as a complication of chronic lung diseases or hypoxia (low oxygen levels in the body). The condition is characterized by enlargement and thickening of the right ventricle of the heart, which results from increased pressure in the pulmonary artery due to damaged or narrowed blood vessels in the lungs. This can lead to symptoms such as shortness of breath, fatigue, swelling in the legs and abdomen, and irregular heart rhythms. The condition can be managed with medications, oxygen therapy, and lifestyle changes, but if left untreated, it can lead to serious complications such as heart failure.

Doxapram is a central stimulant drug that acts on the respiratory system. It is primarily used to stimulate breathing and promote wakefulness in patients who have reduced levels of consciousness or are experiencing respiratory depression due to various causes, such as anesthesia or medication overdose.

Doxapram works by stimulating the respiratory center in the brainstem, increasing the rate and depth of breathing. It also has a mild stimulant effect on the central nervous system, which can help to promote wakefulness and alertness.

The drug is available in various forms, including injectable solutions and inhaled powders. It is typically administered under medical supervision in a hospital or clinical setting due to its potential for causing adverse effects such as agitation, anxiety, and increased heart rate and blood pressure.

It's important to note that doxapram should only be used under the direction of a healthcare professional, as improper use can lead to serious complications.

Levorphanol is a potent opioid analgesic medication used to treat moderate to severe pain. It is a synthetic compound with a chemical structure similar to that of morphine, but it has more potent analgesic and sedative effects. Levorphanol works by binding to opioid receptors in the brain and spinal cord, which reduces the perception of pain and produces a sense of well-being or euphoria.

Levorphanol is available in oral tablet form and is typically used for short-term pain management in patients who are not able to take other opioid medications or who have developed tolerance to them. It has a long duration of action, with effects lasting up to 24 hours after a single dose.

Like all opioids, levorphanol carries a risk of dependence and addiction, as well as serious side effects such as respiratory depression, sedation, and constipation. It should be used with caution in patients with a history of substance abuse or mental illness, and it is not recommended for use in pregnant women or children.

... (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ... Under the brand names Albasine, Aruxil, and Truxil, almitrine-raubasine has been marketed for rehabilitation after stroke, age ... They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in ... "Almitrine Bismesylate + Raubasine , অ্যালমিট্রিন বিসমিসাইলেট + রবাসিন , Indications, Pharmacology, Dosage, Side Effects & other ...
... is part of the core structure for a number of drugs including almitrine, altretamine, cyromazine, ethylhexyl triazone ...
... almitrine (INN) almokalant (INN) almorexant INN almotriptan (INN) almoxatone (INN) almurtide (INN) alnespirone (INN) alniditan ...
... almitrine MeSH D03.383.606.290 - cinnarizine MeSH D03.383.606.320 - cyclizine MeSH D03.383.606.350 - delavirdine MeSH D03.383. ... almitrine MeSH D03.383.931.135 - altretamine MeSH D03.383.931.190 - apazone MeSH D03.383.931.247 - atrazine MeSH D03.383. ...
Other products: Agomelatine (Valdoxan, Melitor, Thymanax) Almitrine (Duxil, Vectarion) Benfluorex (Mediaxal) Carbutamide ( ...
Doxapram R07AB02 Nikethamide R07AB03 Pentetrazol R07AB04 Etamivan R07AB05 Bemegride R07AB06 Prethcamide R07AB07 Almitrine ...
... is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to ...
Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ... Under the brand names Albasine, Aruxil, and Truxil, almitrine-raubasine has been marketed for rehabilitation after stroke, age ... They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in ... "Almitrine Bismesylate + Raubasine , অ্যালমিট্রিন বিসমিসাইলেট + রবাসিন , Indications, Pharmacology, Dosage, Side Effects & other ...
Overall, almitrine increased the PaO2/FiO2 ratio by 50% (p < 0.01), decreased the partial arterial pressure of carbon ... Almitrine could be an interesting therapy in spontaneously breathing patients with COVID-19 treated with HFNO and with ... We prospectively studied the effects of almitrine (16 µg/kg/min over 30 min followed by continuous administration in ... Almitrine, a selective pulmonary vasoconstrictor in hypoxic area, improves oxygenation in mechanically ventilated patients with ...
Almitrine (s). "Spanish toxic oil". Arsenic (s)(d). 2-t-Butylazo- 2- hydroxyl- 5 methylhexane ...
Does Almitrine Restore Halothane-induced Depression of Hypoxic Respiratory Drive? Denham S. Ward, M.D., Ph.D. ...
95. ALMITRINE [ԱԼՄԻՏՐԻՆ] 46. ALEUTIAN MINK DISEASE [ԱԼԵՈՒՏԱՅԻՆ ՋՐԱՔՍԻ ՀԻՎԱՆԴՈՒԹՅՈՒՆ] 96. ALOE [ԱԼՈԷ] ...
Almitrines primary use is as a respiratory stimulant in people with COPD. Almitrine increases ventilation in patients with ... Only one of almitrines metabolites is active, but its potency as a respiratory stimulant is 5 times less than the parent ... Almitrine increases V˙E by increasing VT and/or RR across multiple species ( Dhillon and Barer, 1982, Flandrois and Guerin, ... Almitrine bismesylate was developed in the 1970s as a respiratory stimulant and first commercialized in 1984 when it was ...
Conversely, the use of inhaled nitric oxide and almitrine remains to be specified. The debate concerning the role of ...
This graph shows the total number of publications written about "Vilazodone Hydrochloride" by people in this website by year, and whether "Vilazodone Hydrochloride" was a major or minor topic of these publications ...
... mainly almitrine, administered alone, or in combination with vasodilators. ...
Al-Hilal TA, Hossain MA, Alobaida A, Alam F, Keshavarz A, Nozik-Grayck E, Stenmark KR, German NA, Ahsan F. Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects. J Control Release. 2021 06 10; 334:237-247 ...
Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012 Aug 03; 150(3):575-89 ...
... for Ischemic Stroke Ticagrelor-Drugs for Ischemic Stroke Ticlopidine Hydrochloride-Drugs for Ischemic Stroke Almitrine ...
Almitrine/therapeutic use, Steroids/therapeutic use, Histamine Antagonists/therapeutic use, Nivolumab/therapeutic use, ...
The benefits of almitrine in managing COPD no longer outweigh the risks of marked weight gain and peripheral neuropathy, given ... PRAC concurred with ANSM in its concerns over almitrine, noting that reports of weight loss and neuropathy continue to come in ... French regulators also noted that "the available evidence does not support a role for almitrine as part of current management ... A respiratory stimulant that treats chronic respiratory failure associated with COPD, almitrine (Vectarion, Armanor; Servier) ...
Almitrine (s). "Spanish toxic oil". Arsenic (s)(d). 2-t-Butylazo- 2- hydroxyl- 5 methylhexane ...
Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?. Bendjelid K; Giraud R; Von Düring S. ...
Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury ... Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury ...
Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury ...
Almitrine,create,27-JUN-08,(null),(null) C74242,Sulmarin,create,27-JUN-08,(null),(null) C74243,Ensaculin,create,27-JUN-08,(null ...
Almitrine (substance). Code System Preferred Concept Name. Almitrine (substance). Concept Status. Published. ...
Almitrine Bis(methanesulfonate) Almitrine Bismesylate Almitrine Dimesylate Almitrine Monomesylate Vectarion Pharm Action. ... Almitrine Dimesylate Narrower Concept UI. M0329453. Registry Number. 6RY6V6XM8T. Terms. Almitrine Dimesylate Preferred Term ... Almitrine Monomesylate Narrower Concept UI. M0329452. Registry Number. 106648-10-6. Terms. Almitrine Monomesylate Preferred ... Almitrine Bis(methanesulfonate) Term UI T046758. Date03/04/1989. LexicalTag NON. ThesaurusID NLM (1990). ...
Almitrine Bis(methanesulfonate) Almitrine Bismesylate Almitrine Dimesylate Almitrine Monomesylate Vectarion Pharm Action. ... Almitrine Dimesylate Narrower Concept UI. M0329453. Registry Number. 6RY6V6XM8T. Terms. Almitrine Dimesylate Preferred Term ... Almitrine Monomesylate Narrower Concept UI. M0329452. Registry Number. 106648-10-6. Terms. Almitrine Monomesylate Preferred ... Almitrine Bis(methanesulfonate) Term UI T046758. Date03/04/1989. LexicalTag NON. ThesaurusID NLM (1990). ...
Almitrine Entry term(s):. Almitrine Bis(methanesulfonate). Almitrine Bismesylate. Almitrine Dimesylate. Almitrine Monomesylate ... Almitrine - Preferred Concept UI. M0024158. Scope note. A respiratory stimulant that enhances respiration by acting as an ... Almitrine Dimesylate - Narrower Concept UI. M0329453. Preferred term. Almitrine Dimesylate Entry term(s). Almitrine Bis( ...
... almitrine bismesilate]. PMID- 3505000 TI - [Combination of different inotropic agents in the treatment of chronic refractory ...
Thirty-two patients with acute respiratory distress syndrome received an almitrine infusion trial. In most cases, almitrine was ... A positive response to almitrine was defined by an increase of Pao2/Fio2 ratio greater than or equal to 20% at the end of the ... INTERVENTIONS: Almitrine was considered in patients with severe hypoxemia (Pao2/Fio2 ratio < 150 mm Hg) in addition to the ... Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single- ...
... almitrine, 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives {Bayer} / desferrioxamine / mild hyperthermia [+R ...
Almitrine showed interactions with the Na+/K+ ATPase transporter for Homo sapiens and Mus musculus, indicating a possible ... Among the selected compounds, three demonstrated in vitro anti-T. gondii activity in the nanomolar range (almitrine, bortezomib ... Almitrine demonstrated a Selectivity Index (provided by the ratio between the Half Cytotoxic Concentration against human ...
RESPIRATORY SYSTEM AGENTS ALMITRINE RESPIRATORY SYSTEM AGENTS AMBROXOL RESPIRATORY SYSTEM AGENTS AMINOPHYLLINE RESPIRATORY ... ANTI-ALLERGIC AND RESPIRATORY SYSTEM AG ALMITRINE ANTI-ALLERGIC AND RESPIRATORY SYSTEM AG AMBROXOL ANTI-ALLERGIC AND ...
Almitrine [D03.383.606.130] * Aripiprazole [D03.383.606.170] * Buspirone [D03.383.606.210] * Cinnarizine [D03.383.606.290] ...
... for Ischemic Stroke Ticagrelor-Drugs for Ischemic Stroke Ticlopidine Hydrochloride-Drugs for Ischemic Stroke Almitrine ...
  • Almitrine, a selective pulmonary vasoconstrictor in hypoxic area, improves oxygenation in mechanically ventilated patients with COVID-19 but its effects in spontaneously breathing patients with COVID-19 remain to be determined. (biomedcentral.com)
  • Pharmacological treatment of hypoxemia caused by unipulmonary ventilation with drugs that modify the pulmonary blood flow, mainly almitrine, administered alone, or in combination with vasodilators. (imim.cat)
  • They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. (wikipedia.org)
  • The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer. (wikipedia.org)
  • Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury. (nih.gov)
  • French regulators also noted that "the available evidence does not support a role for almitrine as part of current management of COPD as its benefit is unclear and alternative treatments are available. (medscape.com)